Femeda Ltd has been shortlisted for the Bionow Awards 2018 Product of the Year. Leading the way in innovation, Pelviva® is a Pelvic Floor muscle re-trainer with Reactive Pulse Technology-RPT™ that offers a long-awaited solution to a condition that affects more than one in three women. Pelviva launched into the UK market in October 2018.

The prestigious Bionow Awards acknowledge ingenuity and dedication, and the accomplishments of those who drive innovation and deliver outstanding results. Organised by Bionow, an award-winning specialist organisation serving the life science sector in the North of England, the winners will be announced on the evening of Thursday 29 November at The Mere Golf Resort & Spa.

Andrew Tasker, CEO of Femeda said: “It is a great achievement to have been shortlisted in this category. This recognises the result of 10 years research and development to bring to market a highly consumer acceptable medical device which delivers a clinically proven treatment, addressing the biggest unmet need in female health. The unique development is the result of combining advanced research and patents from University of Manchester with Femeda product development to deliver a product which meets the patient need.”

A lack of market innovation led Femeda Ltd to develop Pelviva – a disposable, clinically effective, discreet and easy-to-use Pelvic Floor muscle re-trainer for the treatment of urinary incontinence (UI) in women.

“A third of all women suffer from bladder leakage1 and Pelviva is the first product of its kind that is really easy to use and is clinically proven to treat bladder leaks,” continues Tasker. “Pelviva is a pioneering medical device that will have a life-changing impact on women’s quality of life.2”


Pelviva incorporates a revolutionary pattern of neuromuscular electrical stimulation using a programme developed by Professor Oldham at The University of Manchester. Each device contains a unique microprocessor that delivers RPT to the Pelvic Floor muscles. The Pelviva reactive pulse mimics the way the body works naturally, causing the Pelvic Floor muscles to contract. This helps restore speed and strength to the power fibres, to prevent bladder leakage when women cough, laugh, sneeze or exercise. It also re-trains the endurance fibres to hold on when a woman urgently needs the toilet, giving back control over urgency bladder leakage.

Pelviva is made of a Body Responsive Foam, which adapts to every woman’s individual shape.3 The unique Pelviva RPT delivers a series of intensive reactive pulses every alternate 10 seconds, to stimulate the Pelvic Floor muscles.3 Each 30 minute treatment using the Pelviva innovative stimulation programme delivers up to 25% greater penetration of the deep pelvic muscle than conventional stimulation.4

Pelviva is supported by a comprehensive package of clinical data. In a 12-week randomised single-blind clinical study involving 123 women, 84% of women using Pelviva reported improvement in bladder control. The Pelviva women reported a four times greater improvement in quality of life versus women who followed an unsupervised Pelvic Floor muscle exercise programme alone.2

Pelviva is available to buy on the website www.pelviva.com and soon to be available in pharmacies.

References:
1. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004 Feb;93(3):324-30.
2. Oldham J, Herbert J, McBride K. Evaluation of a new disposable ‘tampon-like’ electrostimulation technology (Pelviva®) for the treatment of urinary incontinence in women: a 12-week single blind randomized controlled trial. Neurourology Urodynamics 2013; 32(5):460-466. doi 10.1002/nau.22326.
3. Femeda data on file 2014
4. Binder-Macleod S, Lee S, Fritz A, Kucharski L. New Look at Force-Frequency Relationship of Human Skeletal Muscle: Effects of Fatigue. Journal of Neurophysiology 1998; 79:1858-1868